Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells $22,355,820.90 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 22,830 shares of the business's stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company's stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $14.31 during trading hours on Friday, reaching $982.29. 386,557 shares of the company were exchanged, compared to its average volume of 486,930. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market cap of $108.24 billion, a price-to-earnings ratio of 28.60, a P/E/G ratio of 2.01 and a beta of 0.17. The stock's fifty day moving average is $942.41 and its two-hundred day moving average is $906.67. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on REGN. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Wednesday, April 24th. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 price objective for the company. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a report on Wednesday, April 17th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a report on Wednesday, March 13th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $989.36.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Allworth Financial LP grew its holdings in Regeneron Pharmaceuticals by 4.7% during the 3rd quarter. Allworth Financial LP now owns 358 shares of the biopharmaceutical company's stock worth $295,000 after acquiring an additional 16 shares during the period. Beaumont Financial Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 26.7% during the third quarter. Beaumont Financial Advisors LLC now owns 327 shares of the biopharmaceutical company's stock worth $269,000 after purchasing an additional 69 shares during the period. Daiwa Securities Group Inc. increased its holdings in Regeneron Pharmaceuticals by 14.9% in the third quarter. Daiwa Securities Group Inc. now owns 14,572 shares of the biopharmaceutical company's stock valued at $11,908,000 after purchasing an additional 1,892 shares during the last quarter. Csenge Advisory Group acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $241,000. Finally, M&T Bank Corp boosted its holdings in Regeneron Pharmaceuticals by 0.5% during the third quarter. M&T Bank Corp now owns 5,423 shares of the biopharmaceutical company's stock worth $4,463,000 after buying an additional 25 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.